应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00013 和黄医药
交易中 11-19 10:02:38
21.460
-0.240
-1.11%
最高
21.760
最低
21.360
成交量
43.95万
今开
21.700
昨收
21.700
日振幅
1.84%
总市值
187.13亿
流通市值
187.13亿
总股本
8.72亿
成交额
947.49万
换手率
0.05%
流通股本
8.72亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
和黄医药(00013):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据
智通财经 · 08:12
和黄医药(00013):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据
和黄医药(00013.HK):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据
智通财经 · 08:12
和黄医药(00013.HK):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据
和黄医药(00013)在国际会议公布全球首创ATTC候选药物HMPL-A830临床前数据
公告速递 · 08:10
和黄医药(00013)在国际会议公布全球首创ATTC候选药物HMPL-A830临床前数据
异动解读|和黄医药盘中下跌4.51%,医保目录扩围后板块仍承压
行情直击 · 11-18 10:17
异动解读|和黄医药盘中下跌4.51%,医保目录扩围后板块仍承压
和黄医药(00013):爱优特®和沃瑞沙®在国家医保药品目录中覆盖范围进一步扩大
金吾财讯 · 11-16 12:22
和黄医药(00013):爱优特®和沃瑞沙®在国家医保药品目录中覆盖范围进一步扩大
和黄医药盘中涨超3% 花旗将目标价由40.1港元上调至43.2港元
新浪港股 · 11-09
和黄医药盘中涨超3% 花旗将目标价由40.1港元上调至43.2港元
港股异动 | 和黄医药(00013.HK)涨超3% 花旗看好savolitinib商业化前景 药物一线机会仍有上行空间
智通财经 · 11-09
港股异动 | 和黄医药(00013.HK)涨超3% 花旗看好savolitinib商业化前景 药物一线机会仍有上行空间
异动解读|和黄医药盘中上涨5.18%,花旗上调目标价并列为新首选股
行情直击 · 11-09
异动解读|和黄医药盘中上涨5.18%,花旗上调目标价并列为新首选股
花旗:上调和黄医药(00013)目标价至43.2港元 列为新首选股
智通财经 · 11-06
花旗:上调和黄医药(00013)目标价至43.2港元 列为新首选股
大行评级|花旗:上调和黄医药目标价至43.2港元,列为新首选股
格隆汇 · 11-06
大行评级|花旗:上调和黄医药目标价至43.2港元,列为新首选股
异动解读|和黄医药盘中上涨5.67%,索乐匹尼布获FDA孤儿药资格认定
行情直击 · 11-05
异动解读|和黄医药盘中上涨5.67%,索乐匹尼布获FDA孤儿药资格认定
港股异动 | 和黄医药(00013.HK)再涨超4% 索乐匹尼布获FDA授予孤儿药资格认定 用于治疗自身免疫性溶血性贫血
智通财经 · 11-05
港股异动 | 和黄医药(00013.HK)再涨超4% 索乐匹尼布获FDA授予孤儿药资格认定 用于治疗自身免疫性溶血性贫血
和黄医药今日宣布索乐匹尼布获美国食品药品监督管理局(“FDA”)授予孤儿药资格认定(Orphan Drug Design
格隆汇 · 11-05
和黄医药今日宣布索乐匹尼布获美国食品药品监督管理局(“FDA”)授予孤儿药资格认定(Orphan Drug Design
和黄医药(00013)口服Syk抑制剂索乐匹尼布获FDA孤儿药资格 适应症扩至自身免疫性溶血性贫血
公告速递 · 11-05
和黄医药(00013)口服Syk抑制剂索乐匹尼布获FDA孤儿药资格 适应症扩至自身免疫性溶血性贫血
和黄医药(00013.HK)宣布索乐匹尼布(sovleplenib)获FDA孤儿药资格认定用于治疗自身免疫性溶血性贫血
智通财经 · 11-05
和黄医药(00013.HK)宣布索乐匹尼布(sovleplenib)获FDA孤儿药资格认定用于治疗自身免疫性溶血性贫血
和黄医药盘中涨超5%,联合疗法海外获批受理及ESMO数据催化
同花顺 · 11-04
和黄医药盘中涨超5%,联合疗法海外获批受理及ESMO数据催化
CXO板块逆市走强 百济神州(06160)涨5.14%、凯莱英(06821)涨4.19%
金吾财讯 · 11-04
CXO板块逆市走强 百济神州(06160)涨5.14%、凯莱英(06821)涨4.19%
港股异动 | 和黄医药(00013)涨超4% 沃瑞沙®和泰瑞沙®联合疗法在欧洲和日本的监管注册申请已获受理
智通财经 · 11-03
港股异动 | 和黄医药(00013)涨超4% 沃瑞沙®和泰瑞沙®联合疗法在欧洲和日本的监管注册申请已获受理
和黄医药10月无新增发行或股份变动,股本维持USD 150,000,000
公告速递 · 11-02
和黄医药10月无新增发行或股份变动,股本维持USD 150,000,000
【券商聚焦】中信证券:国内医药板块业绩持续修复
金吾财讯 · 11-02
【券商聚焦】中信证券:国内医药板块业绩持续修复
公司概况
公司名称:
和黄医药
所属市场:
SEHK
上市日期:
--
主营业务:
和黄医药(中国)有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动,上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务,包括其他处方药物及保健品的销售、推广、生产及分销。
发行价格:
--
{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":21.46,"timestamp":1795053757718,"preClose":21.7,"halted":0,"volume":439500,"delay":0,"changeRate":-0.011059907834101311,"floatShares":872000000,"shares":872000000,"eps":0.519999,"marketStatus":"交易中","change":-0.24,"latestTime":"11-19 10:02:38","open":21.7,"high":21.76,"low":21.36,"amount":9474860,"amplitude":0.018433,"askPrice":21.46,"askSize":21500,"bidPrice":21.4,"bidSize":48500,"shortable":3,"etf":0,"ttmEps":0.158332,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1795060800000},"marketStatusCode":2,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":21.7,"openAndCloseTimeList":[[1795051800000,1795060800000],[1795064400000,1795075200000]],"volumeRatio":1.132517,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013/wiki","defaultTab":"wiki","newsList":[{"id":"2684106619","title":"和黄医药(00013):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2684106619","media":"智通财经","labels":["conferences"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684106619?lang=zh_cn&edition=full","pubTime":"2026-11-19 08:12","pubTimestamp":1795047155,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和黄医药 发布公告,于2026年11月18至20日在西班牙巴塞罗那举行的EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布HMPL-A830的临床前数据。HMPL-A830对EGFR阳性的细胞表现出高亲和力,并能迅速被内吞进入细胞内部 。在小鼠模型中,HMPL-A830在多种携带KRAS变异的EGFR阳性肿瘤模型中均展现出强大、剂量依赖性的抗肿瘤疗效。和记黄埔医药(上海)有限公司将负责HMPL-A830的全球I期开发项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1525360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据","news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1588","00013","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684591066","title":"和黄医药(00013.HK):于第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上公布 HMPL-A830临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2684591066","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684591066?lang=zh_cn&edition=full","pubTime":"2026-11-19 08:12","pubTimestamp":1795047155,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","00013","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156643489","title":"和黄医药(00013)在国际会议公布全球首创ATTC候选药物HMPL-A830临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1156643489","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156643489?lang=zh_cn&edition=full","pubTime":"2026-11-19 08:10","pubTimestamp":1795047047,"startTime":"0","endTime":"0","summary":"2026年11月19日,和黄医药发布自愿性公告称,公司已在2026年11月18日至20日于西班牙巴塞罗那举行的第38届EORTC-NCI-AACR分子靶向和癌症治疗国际会议上,公布了抗体靶向偶联药物候选药物HMPL-A830的临床前研究结果。该药物由高选择性且强效的KRAS小分子抑制剂与抗表皮生长因子受体抗体偶联组成,为全球首创ATTC。在携带KRAS变异的EGFR阳性小鼠肿瘤模型中,HMPL-A830显示出强大且剂量依赖的抗肿瘤活性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160755969","title":"异动解读|和黄医药盘中下跌4.51%,医保目录扩围后板块仍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1160755969","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160755969?lang=zh_cn&edition=full","pubTime":"2026-11-18 10:17","pubTimestamp":1794968264,"startTime":"0","endTime":"0","summary":"11月18日,和黄医药盘中下跌4.51%,报21.58港元,成交额2248.89万港元。近期消息面上,公司宣布爱优特、沃瑞沙和苏泰达继续纳入新版国家医保药品目录,并新增部分适应症覆盖,其中沃瑞沙获纳入联合奥希替尼用于EGFR突变、经EGFR-TKI治疗后进展且伴MET扩增的晚期或转移性非鳞状非小细胞肺癌患者。不过,从盘面看,制药板块整体走弱,同业个股亦普遍下跌,中国生物制药、石药集团、翰森制药、恒瑞医药及凯莱英跌幅居前,显示此次回落更偏向行业层面压力下的个股波动。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和黄医药盘中下跌,医保扩围仍难振板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683662712","title":"和黄医药(00013):爱优特®和沃瑞沙®在国家医保药品目录中覆盖范围进一步扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2683662712","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683662712?lang=zh_cn&edition=full","pubTime":"2026-11-16 12:22","pubTimestamp":1794802928,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和黄医药 发布公告称,继与中国国家医疗保障局的医保续约,爱优特、沃瑞沙和苏泰达将继续获纳入自2027年1月1日起生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》。本次更新涵盖新适应症纳入、现有适应症续约,以及现行多年期协议下的持续保障。沃瑞沙获纳入联合奥希替尼用于治疗表皮生长因子受体基因突变阳性经EGFR-TKI治疗后进展的伴MET扩增的局部晚期或转移性非鳞状非小细胞肺癌患者。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/NmY0NGUwYzEyZTE3Njc2MTkyNTUxNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmY0NGUwYzEyZTE3Njc2MTkyNTUxNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1996115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","BK1191","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682878221","title":"和黄医药盘中涨超3% 花旗将目标价由40.1港元上调至43.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682878221","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682878221?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:59","pubTimestamp":1794193140,"startTime":"0","endTime":"0","summary":"模拟交易客户端和黄医药盘中涨超3%,截至发稿,股价上涨2.42%,现报23.72港元,成交额7757.499万港元。花旗发布研报称,该行于11月5日与SANOVO主要研究者举行专家会议,进一步强化对savolitinib在一线及osimertinib治疗后EGFR突变非小细胞肺癌潜力的正面看法,维持“买入/高风险”评级,并将和黄医药列为新首选股,目标价由40.1港元上调至43.2港元。该行上调2027/2028财年收入预测4%及2%,上调每股盈测15%及5%,主要反映savolitinib潜在海外获批及流行病学模型调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-09/doc-iniyazee6646835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00013","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682878980","title":"港股异动 | 和黄医药(00013.HK)涨超3% 花旗看好savolitinib商业化前景 药物一线机会仍有上行空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2682878980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682878980?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:45","pubTimestamp":1794192304,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1587","BK1588","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119445757","title":"异动解读|和黄医药盘中上涨5.18%,花旗上调目标价并列为新首选股","url":"https://stock-news.laohu8.com/highlight/detail?id=1119445757","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119445757?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:56","pubTimestamp":1794189389,"startTime":"0","endTime":"0","summary":"11月9日,和黄医药盘中上涨5.18%,报24.36港元,成交额5720.63万港元。花旗在11月6日将公司列为新首选股,目标价由40.1港元上调至43.2港元,并维持买入/高风险评级。该行称,11月5日与SANOVO主要研究者会面后,进一步看好savolitinib在一线及奥希替尼治疗后EGFR突变非小细胞肺癌中的潜力,同时上调2027及2028财年收入预测4%及2%,并上调每股盈利预测15%及5%,主要反映潜在海外获批预期。和黄医药(中国)有限公司是一间主要从事制造及销售药物的投资控股公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药盘中上涨,花旗列为新首选股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681831431","title":"花旗:上调和黄医药(00013)目标价至43.2港元 列为新首选股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681831431","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681831431?lang=zh_cn&edition=full","pubTime":"2026-11-06 13:58","pubTimestamp":1793944684,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研报称,该行于11月5日与SANOVO主要研究者举行专家会议,进一步强化对savolitinib在一线及osimertinib治疗后EGFR突变非小细胞肺癌潜力的正面看法,维持“买入/高风险”评级,并将和黄医药列为新首选股,目标价由40.1港元上调至43.2港元。该行上调2027/2028财年收入预测4%及2%,上调每股盈测15%及5%,主要反映savolitinib潜在海外获批及流行病学模型调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681836022","title":"大行评级|花旗:上调和黄医药目标价至43.2港元,列为新首选股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681836022","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681836022?lang=zh_cn&edition=full","pubTime":"2026-11-06 13:09","pubTimestamp":1793941750,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0098860793.USD","EWH","LU0320765646.SGD","LU1162221912.USD","LU0477156953.USD","BK4559","FTXO","IYF","LU0170899867.USD","LU1144417596.USD","LU1244550494.USD","LU1244550577.SGD","LU0648001328.SGD","LU2360032135.SGD","BK4534","LU1668664300.SGD","LU2125154778.USD","BK4585","LU1074936037.SGD","LU0052756011.USD","LU0130102774.USD","LU1064131342.USD","LU2417539215.USD","LU1366192091.USD","BK4504","LU2236285917.USD","LU2462157665.USD","LU0162691827.USD","LU0106831901.USD","LU0310800965.SGD","LU2456880835.USD","BK1191","LU2264538146.SGD","IE00BSNM7G36.USD","LU1267930227.SGD","BK4588","BK4207","BK1588","LU0130517989.USD","LU0072461881.USD","LU2125154935.USD","LU0980610538.SGD","LU0203345920.USD","LU1506573853.SGD","TFNS","LU0203347892.USD","00013","LU0314106906.USD","LU1791807156.HKD","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140691555","title":"异动解读|和黄医药盘中上涨5.67%,索乐匹尼布获FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1140691555","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140691555?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:23","pubTimestamp":1793845383,"startTime":"0","endTime":"0","summary":"11月5日,和黄医药盘中上涨5.67%,报23.14港元,成交额5862.22万港元。消息面上,公司当日宣布自主研发的口服Syk抑制剂索乐匹尼布获FDA授予孤儿药资格认定,用于治疗自身免疫性溶血性贫血。这是索乐匹尼布继10月获FDA授予用于原发性免疫性血小板减少症孤儿药资格后,再获一项美国孤儿药认定,显示该产品在免疫性疾病领域的适应症拓展持续推进,也为公司创新药管线再添催化。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和黄医药上涨,索乐匹尼布获FDA孤儿药资格","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681501802","title":"港股异动 | 和黄医药(00013.HK)再涨超4% 索乐匹尼布获FDA授予孤儿药资格认定 用于治疗自身免疫性溶血性贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=2681501802","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681501802?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:56","pubTimestamp":1793843786,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1588","BK1587","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681092424","title":"和黄医药今日宣布索乐匹尼布获美国食品药品监督管理局(“FDA”)授予孤儿药资格认定(Orphan Drug Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2681092424","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681092424?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:13","pubTimestamp":1793837616,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK1588","BK1587","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125704645","title":"和黄医药(00013)口服Syk抑制剂索乐匹尼布获FDA孤儿药资格 适应症扩至自身免疫性溶血性贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=1125704645","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125704645?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:12","pubTimestamp":1793837549,"startTime":"0","endTime":"0","summary":"2026年11月5日,和黄医药(中国)有限公司公告,其自主研发的口服脾酪氨酸激酶抑制剂索乐匹尼布已获得美国食品药品监督管理局授予的孤儿药资格认定,用于治疗自身免疫性溶血性贫血。这是继2026年10月获批原发性免疫性血小板减少症后,该产品取得的第二项美国FDA孤儿药资格认定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681092624","title":"和黄医药(00013.HK)宣布索乐匹尼布(sovleplenib)获FDA孤儿药资格认定用于治疗自身免疫性溶血性贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=2681092624","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681092624?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:04","pubTimestamp":1793837042,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","00013","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680089926","title":"和黄医药盘中涨超5%,联合疗法海外获批受理及ESMO数据催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2680089926","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680089926?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:49","pubTimestamp":1793771340,"startTime":"0","endTime":"0","summary":"11月4日,和黄医药(00013.HK)盘中涨超5%,截至13时44分,涨5.06%,报21.600港元/股,成交额11199.04万港元。消息面上,11月2日,花旗发表研究报告指,ESMO2026中国原研资产于多项全球关键研 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261104/c681448797.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261104/c681448797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["00013","BK1588","BK1191","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680519700","title":"CXO板块逆市走强 百济神州(06160)涨5.14%、凯莱英(06821)涨4.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680519700","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680519700?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:34","pubTimestamp":1793759693,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块逆市走强,百济神州 涨5.14%,凯莱英涨4.19%,药明康德涨3.92%,药明生物涨3.58%,科伦博泰生物涨2.89%,药明合联涨2.44%,和铂医药-B涨1.76%,康龙化成涨1.46%,和黄医药涨1.17%。湘财证券表示,CXO龙头药明康德三季报超预期、指引上修,印证CXO由周期修复转向CRDMO结构性重估。维持药品行业“买入”评级,建议关注创新化学制剂及创新药产业链上游CXO公司。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995187","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128522744.USD","00013","02269","LU0823426480.USD","LU0516422440.USD","SG9999002463.SGD","LU1831875114.USD","06990","BK1574","CXO","LU1720050803.USD","LU0320764243.SGD","LU0051755006.USD","LU0043850808.USD","LU0456827905.SGD","LU0828237510.HKD","LU0229945570.USD","LU0326950275.SGD","BK0132","LU0072913022.USD","LU0348766576.USD","LU0463099449.HKD","LU0588546209.SGD","02359","688235","LU0359202008.SGD","LU1719994722.HKD","06160","LU0327786744.USD","LU1242518857.USD","KURE","LU0128526141.USD","LU2045819591.USD","02142","BK1141","LU2476274720.SGD","LU0516423091.SGD","02268","ONC","WX","LU0823426308.USD","06821","LU2476274308.USD","LU0501845795.SGD","LU0502904849.HKD","SG9999002562.SGD","LU0455707207.USD","03759","002821","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680812718","title":"港股异动 | 和黄医药(00013)涨超4% 沃瑞沙®和泰瑞沙®联合疗法在欧洲和日本的监管注册申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2680812718","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680812718?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:53","pubTimestamp":1793670797,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,和黄医药涨超4%,截至发稿,涨3.86%,报21.52港元,成交额1.48亿港元。消息面上,11月2日,和黄医药发布公告,沃瑞沙和泰瑞沙联合疗法在欧洲和日本的监管注册申请已获受理。继2026年9月向美国食品药品监督管理局递交该联合疗法用于同一适应症的的新药上市申请后,此次在欧洲和日本的监管注册申请获受理,标志着推动这一创新靶向联合疗法惠及全球患者的进程取得进一步进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","KCAI","BK4588","BK4585","00013","BK1588","VXUS","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108408686","title":"和黄医药10月无新增发行或股份变动,股本维持USD 150,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=1108408686","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108408686?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:36","pubTimestamp":1793608570,"startTime":"0","endTime":"0","summary":"2026年11月2日,和黄医药披露截至2026年10月31日的股份变动月报表。公告显示,截至本月底,公司法定/注册股本总额仍为USD 150,000,000,法定/注册股本数量1,500,000,000股,环比无变动。在股权激励方面,2015年4月24日有条件采纳、并于2026年5月12日到期的认股权计划在月初共有22,868,897份期权,期间857,065份失效后,月末结存22,011,832份,期间无期权行使或新增授予。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券:国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略,“十五五”开局之年,医药行业首次列为国家新兴支柱产业,紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势,叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下,该机构看到2026H1国内医药板块业绩持续修复,尤其是创新药、创新器械等新兴产业板块。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","09966","09939","01276","06990","159938","02162","LU0823426480.USD","LU1064131003.USD","02269","09996","06030","LU0828237510.HKD","06996","IE00B031HY20.USD","LU0607220059.USD","600030","03692","LU1794554557.SGD","LU2488822045.USD","03759","LU1969619763.USD","LU0708995153.HKD","LU0039217434.USD","06160","02596","02273","LU0979878070.USD","KURE","01801","LU0348766576.USD","LU0348825331.USD","01093","06078","01951","KCE","00013","HK0000320264.USD","LU0708995583.HKD","02268","06821","09926","LU0455707207.USD","02096","01952","BK0028","01548","01177","LU0588546209.SGD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0905},{"period":"1month","weight":-0.026},{"period":"3month","weight":0.0982},{"period":"6month","weight":0.132},{"period":"1year","weight":-0.0565},{"period":"ytd","weight":0.0524}],"compareEarnings":[{"period":"1week","weight":-0.042},{"period":"1month","weight":-0.0369},{"period":"3month","weight":-0.0935},{"period":"6month","weight":-0.0903},{"period":"1year","weight":-0.1016},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药(中国)有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动,上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务,包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.004362},{"month":7,"riseRate":1,"avgChangeRate":0.132805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.047962},{"month":9,"riseRate":0.666667,"avgChangeRate":0.027356},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.049929},{"month":11,"riseRate":0.5,"avgChangeRate":0.123354},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}